Abstract Number: 1456 • 2013 ACR/ARHP Annual Meeting
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Background/Purpose: Low drug levels of anti-Tumor Necrosis Factor (TNF) therapies are related to poorer response in patients with rheumatoid arthritis (RA). Furthermore, anti-drug antibodies (ADA)…Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…Abstract Number: 1417 • 2013 ACR/ARHP Annual Meeting
Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase 3 Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis
Background/Purpose: For anti-TNFα agents, infections and malignancies are key safety concerns. It is unknown whether safety events are driven by peak (Cmax), trough (Cmin), average…Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…Abstract Number: 1419 • 2013 ACR/ARHP Annual Meeting
Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial
Background/Purpose: The best treatment option after a patient has failed a first TNFi is still unknown. Therefore the objective of this randomized open label study…Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…Abstract Number: 1421 • 2013 ACR/ARHP Annual Meeting
Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study
Background/Purpose: The identification of predictors of good response to biologic therapy is needed in the perspective of personalized medicine. To determine the predicting factors of efficacy…Abstract Number: 1422 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis
Background/Purpose: Iguratimod is a newly-developed disease-modifying antirheumatic drug (DMARD) that was approved in Japan in September 2012. It has been reported to suppress tumor necrosis…Abstract Number: 1423 • 2013 ACR/ARHP Annual Meeting
The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis
Background/Purpose : The impact of Body mass Index (BMI) on efficacy of TNF blocking therapy is an important question, as adipose tissue appears to have…Abstract Number: 1424 • 2013 ACR/ARHP Annual Meeting
Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare
Background/Purpose: A limited number of rheumatoid arthritis (RA) patients are managed with a single disease-modifying anti-rheumatic drug (DMARD). Previous studies have suggested that DMARD naïve…Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…Abstract Number: 1426 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Spermidine/Spermine N1-Acetyltransferase Activity – a New Therapeutical Concept In Rheumatoid Arthritis
Background/Purpose: Spermine/spermidine N1-acetyltransferase (SSAT1) and polyamine modulating factor 1 (PMF1) are increased in rheumatoid arthritis synovial fibroblasts (RASF). Since PMF1 regulates the expression of SSAT1,…Abstract Number: 1427 • 2013 ACR/ARHP Annual Meeting
Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a serious autoimmune disease that significantly impacts patients’ quality of life. Several approved biologic drugs targeting tumor necrosis factor (TNF)…Abstract Number: 1428 • 2013 ACR/ARHP Annual Meeting
The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA)
Background/Purpose: The BREVACTA study assessed the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) in pts with moderate to severe RA who had an inadequate response…Abstract Number: 1429 • 2013 ACR/ARHP Annual Meeting
Adiponectin Levels Are Increased After Tocilizumab Therapy Among Adults With Rheumatoid Arthritis: Results From The Measure Study
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients (pts) with rheumatoid arthritis (RA). Adiponectin has been shown to have anti-inflammatory and…
ACR Meeting Abstracts